Reversing the Antibiotic Apocalypse—A Global Call to Action
By Biosortia Microbiomics, May 28, 2026 Biosortia: Reversing the Antibiotic Apocalypse—A Global Call to Action WATCH NOW 1. The Existential Threat: Chronic Infections and the Silent Biofilm Catastrophe The world stands on the brink of a medical crisis in which common infections are becoming untreatable. This silent catastrophe is driven by the “Biofilm Barrier”—a sophisticated, multicellular, fortress-like architecture that shields
Continue Reading
Has synthetic chemical screening hit the wall?
By Ross Youngs, May 28, 2026 Has synthetic chemical screening hit the wall? Traditional pharma libraries often yield hit rates below 0.1% when searching for complex aging targets. It’s a massive needle-in-a-haystack problem that costs millions and takes years. Even then, once de-risked preclinical, it takes 40 programs to get an approval. Microbiome-based starting point, once de-risked, takes only 4.4
Continue ReadingMicrobiome Metabolic Fingerprinting: The Critical Control Layer for Deep Space Survival and Terrestrial Health (D2)
By Ross Youngs, November 26, 2025. Microbiome Metabolic Fingerprinting: The Critical Control Layer for Deep Space Survival and Terrestrial Health (D2) The two defining challenges of the coming century—reversing the decline in pharmaceutical R&D productivity on Earth and enabling sustainable human habitation in space—are usually treated as separate problems. In reality, they share a common dependency: access to and control over
Continue Reading
Unveiling Hidden Microbial . . . GLP-1
By Ross Youngs, November 25, 2025. Unveiling Hidden Microbial . . . GLP-1 [video_popup url="https://www.youtube.com/watch?v=xOv5lPKq1KQ" text="WATCH NOW"] Breaking Research: A Differentiated, Oral Approach to Weight Management is Emerging from the Microbial “Dark Matter. “Our latest white paper, “Unveiling Hidden Microbial Metabolites for Polypharmacology in Obesity Therapeutics” (Draft 2), reveals a novel, natural-product-derived scaffold with unimolecular polypharmacology—a single molecule coordinating multiple appetite
Continue Reading
Reversing Eroom’s Law: Finitude and Dilution in Small-Molecule Discovery
By Ross Youngs, October 31, 2025. Reversing Eroom’s Law: Finitude and Dilution in Small-Molecule Discovery Abstract Drug discovery productivity—measured as clinically viable new molecules per research has declined for decades, a trend known as Eroom’s Law. This paradox persists despite advances in screening, computing, and artificial intelligence. Here we show that it stems from two forces: the finite diversity of nature’s
Continue ReadingA New Paradigm for Accredited Investors: Equity vs. Direct Asset Tokenization
By Ross Youngs, July 26, 2025 A New Paradigm for Accredited Investors: Equity vs. Direct Asset Tokenization Impact for funding under Reg D by the Newly Approved National Legislation Abstract Drug discovery productivity—measured as clinically viable new molecules per research has declined for decades, a trend known as Eroom’s Law. This paradox persists despite advances in screening, computing, and artificial
Continue Reading
White Paper — The Beauty of Microbial Natural Products: Selective Polypharmacology ≠ Promiscuity
By Ross Youngs, October 10, 2025 White Paper — The Beauty of Microbial Natural Products Abstract: For decades, the ‘one‐drug, one‐target’ paradigm shaped discovery strategies. Although this approach yielded many important medicines, it often underperforms against complex, multi‐factorial diseases in which networks of proteins and pathways adapt to single node blockade. Network pharmacology reframes this challenge by embracing polypharmacology—intentional, selective engagement
Continue ReadingThe Evolutionary Advantage: Why Microbial Chemistry Wins in Drug Discovery & Approval
By Ross Youngs, September 23, 2025 The Evolutionary Advantage: Why Microbial Chemistry Wins in Drug Discovery & Approval Quantifying Success and Capitalized Cost Savings from Lead Identification Executive Summary The classic ‘magic‐bullet’ strategy—maximally selective ligands for single targets—is well suited to simple causal architectures but less effective for diseases driven by robust and redundant networks (e.g., cancer, metabolic and neurodegenerative disorders).
Continue Reading
Ross Youngs “A conversation with a genius”
By Ross Youngs, November 27, 2024 “A conversation with a genius” Key points: The bottleneck in drug discovery suggests we need 1,000,000,000,000,000,000,000,000,000 years or more. Even with generous assumptions and the full force of global computing power, creating and testing all possible drug-like molecules within a reasonable timeframe remains a distant prospect. However, this thought experiment
Continue Reading
Engineers Versus Scientists ChatGPT
By Ross Youngs, March 24, 2023. Engineers Versus Scientists ChatGPT Just some leading questions to ChatGPT with responses and pushback. A fun Friday read. I am focused on executing a new technology to bring the best small molecules into drug discovery research, and funding sources always ask what is your clinical proof – or what is
Continue Reading